Our top pick for
Venus Concept Inc is a medical devices business based in the US. Venus Concept shares (VERO) are listed on the NASDAQ and all prices are listed in US Dollars. Venus Concept employs 384 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.84|
|52-week range||$1.60 - $3.44|
|50-day moving average||$2.29|
|200-day moving average||$2.28|
|Wall St. target price||$5.55|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.65|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-5.64%|
|1 month (2021-09-23)||-27.56%|
|3 months (2021-07-23)||-25.51%|
|6 months (2021-04-23)||-1.60%|
|1 year (2020-10-23)||-27.56%|
|2 years (2019-10-24)||324.84%|
|3 years (2018-10-24)||13.58%|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$94.9 million|
|Gross profit TTM||$51.4 million|
|Return on assets TTM||-6.71%|
|Return on equity TTM||-81.74%|
|Market capitalisation||$105.6 million|
TTM: trailing 12 months
There are currently 1.1 million Venus Concept shares held short by investors – that's known as Venus Concept's "short interest". This figure is 0.1% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting Venus Concept shares can be evaluated.
Venus Concept's "short interest ratio" (SIR) is the quantity of Venus Concept shares currently shorted divided by the average quantity of Venus Concept shares traded daily (recently around 199569.65265082). Venus Concept's SIR currently stands at 5.47. In other words for every 100,000 Venus Concept shares traded daily on the market, roughly 5470 shares are currently held short.
However Venus Concept's short interest can also be evaluated against the total number of Venus Concept shares, or, against the total number of tradable Venus Concept shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Venus Concept's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Venus Concept shares in existence, roughly 20 shares are currently held short) or 0.0343% of the tradable shares (for every 100,000 tradable Venus Concept shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Venus Concept.
Find out more about how you can short Venus Concept stock.
We're not expecting Venus Concept to pay a dividend over the next 12 months.
Venus Concept's shares were split on a 1:15 basis on 7 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Venus Concept shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Venus Concept shares which in turn could have impacted Venus Concept's share price.
Venus Concept Inc. , a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Velocity and Venus Epileve, a diode laser device for hair removal, permanent hair reduction, and treatment of ingrown hair; and Venus Fiore that is used for the treatment of vaginal canal, labia skin tightening, and mons pubis. The company also offers Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin; Venus Freeze Plus, a noninvasive device used in dermatologic and general surgical procedures for females for the noninvasive treatment of moderate to severe facial wrinkles and rhytides; Venus Bliss, a device is used for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance. In addition, it provides NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system; and ARTAS and ARTAS iX, a robotic systems to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.